FDA Oversight Risk

Minimalist regulatory intelligence visual showing fragmented signal lines converging into a single controlled channel, representing enforcement-driven market normalization.

FDA Oversight Risk

Novo vs. Hims, Part II: Enforcement Didn’t End the Story — It Rewired the Channel

Hims’ collaboration with Novo and its move away from mass advertising of compounded GLP-1s suggests a tighter distribution lane: platform participation continues, but more explicitly aligned to FDA-approved products and individualized “clinically necessary” exceptions.

Minimalist regulatory intelligence visual showing signal lines diffusing across a dark grid, illustrating oversight strain, data gaps, and governance traceability.

FDA Oversight Risk

FDA Oversight Is Losing Resolution — And Industry May Increasingly Be Expected to Close the Gap

GAO warnings that FDA oversight is constrained by data gaps and complexity suggest a quiet shift in expectations, with industry increasingly expected to supply clearer, earlier, and more continuous evidence of risk control.

Free risk assessment →